Orbits Oncology applies deep learning and specialized computer vision to analyze tumor organoids. This process builds predictive models forecasting real-world patient therapy response based on high-resolution imaging data. The platform delivers automated response metrics to improve clinical prediction in oncology treatment selection.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer drug development relies heavily on animal models, which often fail to accurately predict drug responses in human patients. This can lead to costly clinical trials with high failure rates and delays in bringing effective treatments to market. Furthermore, preclinical decision-making lacks patient-specific data, hindering the development of personalized cancer therapies.
Solution
Orbits Oncology offers an AI-driven platform that leverages live-cell imaging and digital organoid analysis to transform patient tumor data into actionable insights for cancer drug development. The platform uses patient-derived tumor organoids and advanced image analysis techniques to provide rapid, patient-relevant analysis of drug responses. By automating the detection, tracking, and measurement of organoid responses to drugs, the platform generates quantitative metrics that can be used to predict clinical outcomes. This approach reduces the reliance on animal models and enables researchers to make more informed preclinical and clinical decisions, ultimately accelerating the development of effective, personalized cancer treatments.
Target Audience
Orbits Oncology primarily serves pharmaceutical companies, biotech firms, and academic research institutions involved in cancer drug discovery and development.
Features
- Live-cell imaging of patient-derived tumor organoids to capture dynamic drug responses
- Automated detection and tracking of organoids using advanced computer vision algorithms
- Quantitative analysis of drug effects through metrics such as Normalized Organoid Growth Rate (NOGR)
- AI-powered clinical prediction models to forecast patient outcomes based on organoid drug responses
- High-throughput screening capabilities for efficient drug discovery and development
- Integrated image and data analysis pipelines for seamless organoid screening
- Secure data processing and storage to ensure data integrity and compliance